CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Objective. To better understand attributes of ART-associated HIV-induced T-cell responses that might be therapeutically harnessed. Methods. CD8(+) T-cell responses were evaluated in some HIV-1 chronically infected participants of the fixed duration STI substudy of the DART trial. Magnitudes, breadth...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Serwanga, J, Mugaba, S, Betty, A, Pimego, E, Walker, A, Munderi, P, Gilks, C, Gotch, F, Grosskurth, H, Kaleebu, P
Formato:	Journal article
Idioma:	English
Publicado em:	2011

Registros relacionados

CD8+ T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+ T Cells <200 Cell/μL: The DART Trial STI Substudy
por: Jennifer Serwanga, et al.
Publicado em: (2011-01-01)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
por: Munderi, P, et al.
Publicado em: (2011)

Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.
por: Jennifer Serwanga, et al.
Publicado em: (2009-01-01)

P16-03. Persistence of robust cross-reactive group M consensus T-cell responses in a chronic HIV-1 clade A1 and D-infected Ugandan population
por: Ndembi NN, et al.
Publicado em: (2009-10-01)

P20-10. Differences in patterns of Gag-induced immunogenetic pressure occur between clades A and D chronic HIV-1 infection in a Ugandan population
por: Lyagoba F, et al.
Publicado em: (2009-10-01)

Interferon-gamma Responses to HIV-1 Clade A and D Peptides in Ugandan Serodiscordant Couples - the CHAVI 002 Protocol
por: Pala, P, et al.
Publicado em: (2008)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
por: Munderi, P, et al.
Publicado em: (2010)

DART and laboratory monitoring of HIV treatment Reply
por: Walker, A, et al.
Publicado em: (2010)

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms
por: Paola Circosta, et al.
Publicado em: (2018-04-01)

Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.
por: Edward Wright, et al.
Publicado em: (2011-01-01)

Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
por: DART Trial Team
Publicado em: (2008)

The role of tumor cells in the modification of T lymphocytes activity &#8212; the expression of the early CD69<sup>+</sup>, CD71<sup>+</sup> and the late CD25<sup>+</sup>, CD26<sup>+</sup>, HLA/DR<sup>+</sup> activation markers on T CD4<sup>+</sup> and CD8<sup>+</sup> cells in squamous cell laryngeal carcinoma. Part I
por: Magdalena Bryś, et al.
Publicado em: (2012-01-01)

CD3<sup>+</sup>/CD16<sup>+</sup>CD56<sup>+</sup> cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma
por: Jacek Roliński, et al.
Publicado em: (2011-04-01)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
por: Gilks, C, et al.
Publicado em: (2013)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
por: Marina Tuyishime, et al.
Publicado em: (2021-08-01)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
por: Kikaire, B, et al.
Publicado em: (2007)

Hookworm infection is associated with decreased CD4+ T cell counts in HIV-infected adult Ugandans.
por: Bozena M Morawski, et al.
Publicado em: (2017-05-01)

CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans.
por: Stanton, T, et al.
Publicado em: (2004)

Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor &#8212; the expression of the early CD69<sup>+</sup>, CD71<sup>+</sup>and the late CD25<sup>+</sup>, CD26<sup>+</sup>, HLA/DR <sup>+</sup> activation markers on T CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes in squamous cell laryngeal carcinoma. Part II
por: Przemysław Lewkowicz, et al.
Publicado em: (2012-01-01)

Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control
por: Anshika Jain, et al.
Publicado em: (2024-05-01)

Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study
por: Annemarie Namuniina, et al.
Publicado em: (2023-01-01)

Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study.
por: Annemarie Namuniina, et al.
Publicado em: (2023-01-01)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
por: Ssali, F, et al.
Publicado em: (2006)

Immunological predictors of CD4<sup>+ </sup>T cell decline in antiretroviral treatment interruptions
por: Gonzalez-García Juan, et al.
Publicado em: (2008-02-01)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
por: Walker, A, et al.
Publicado em: (2010)

Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
por: C Scott Mahan, et al.
Publicado em: (2010-02-01)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
por: Mugyenyi, P, et al.
Publicado em: (2010)

lt- ja sti-liiteliste adverbide kasutuse muutumine eesti kirjakeeles
por: Annika Küngas
Publicado em: (2013-12-01)

Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.
por: Michael A Eller, et al.
Publicado em: (2011-04-01)

MicroRNA-Mediated Restriction of HIV-1 in Resting CD4<sup>+</sup> T Cells and Monocytes
por: Andrew P. Rice, et al.
Publicado em: (2012-08-01)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
por: Gibb, D, et al.
Publicado em: (2012)

Cardiometabolic risk among HIV Positive Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy
por: Patrick Kazooba, et al.
Publicado em: (2017-05-01)

Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
por: Jennifer Serwanga, et al.
Publicado em: (2023-05-01)

Transforming Teachers’ Instructional Design for Enhancing Critical Thinking in Ugandan Schools
por: Mauro Giacomazzi, et al.
Publicado em: (2023-04-01)

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
por: Derek D Sloan, et al.
Publicado em: (2015-01-01)

Computational MHC-I epitope predictor identifies 95% of experimentally mapped HIV-1 clade A and D epitopes in a Ugandan cohort
por: Daniel Lule Bugembe, et al.
Publicado em: (2020-02-01)

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
por: Plana, M, et al.
Publicado em: (2004)

B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.
por: Peter Oballah, et al.
Publicado em: (2011-01-01)

Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay
por: Natalia Fernandez, et al.
Publicado em: (2022-12-01)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Anne W J Martens, et al.
Publicado em: (2020-05-01)